Advertisement
BIIB or CVM or TRAW
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 0 FA rating(s) are green whileCVM’s FA Score has 0 green FA rating(s), and TRAW’s FA Score reflects 1 green FA rating(s).
- BIIB’s FA Score: 0 green, 5 red.
- CVM’s FA Score: 0 green, 5 red.
- TRAW’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 2 TA indicator(s) are bullish while CVM’s TA Score has 5 bullish TA indicator(s), and TRAW’s TA Score reflects 4 bullish TA indicator(s).
- BIIB’s TA Score: 2 bullish, 6 bearish.
- CVM’s TA Score: 5 bullish, 4 bearish.
- TRAW’s TA Score: 4 bullish, 5 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а -3.46% price change this week, while CVM (@Biotechnology) price change was +19.42% , and TRAW (@Biotechnology) price fluctuated -8.88% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.79%. For the same industry, the average monthly price growth was +6.07%, and the average quarterly price growth was +13.61%.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.32%. For the same industry, the average monthly price growth was +16.82%, and the average quarterly price growth was +37.20%.
Reported Earning Dates
BIIB is expected to report earnings on Oct 22, 2025.
CVM is expected to report earnings on May 15, 2025.
TRAW is expected to report earnings on May 15, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (+0.79% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+1.32% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BIIB | CVM | TRAW | |
| Capitalization | 31.3B | 48.5M | 8.21M |
| EBITDA | 2.04B | -21.96M | -24.89M |
| Gain YTD | -16.296 | -31.816 | -82.658 |
| P/E Ratio | 26.95 | N/A | N/A |
| Revenue | 9.84B | 0 | 227K |
| Total Cash | 1.05B | 1.92M | 15.9M |
| Total Debt | 7.34B | 10.5M | N/A |
BIIB | CVM | TRAW | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 70 | 2 | 8 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 98 Overvalued | 27 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 71 | 99 | 100 | |
PRICE GROWTH RATING 1..100 | 62 | 34 | 65 | |
P/E GROWTH RATING 1..100 | 95 | 49 | 100 | |
SEASONALITY SCORE 1..100 | n/a | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TRAW's Valuation (27) in the Biotechnology industry is somewhat better than the same rating for BIIB (87) and is significantly better than the same rating for CVM (98). This means that TRAW's stock grew somewhat faster than BIIB’s and significantly faster than CVM’s over the last 12 months.
TRAW's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as BIIB (100) and is in the same range as CVM (100). This means that TRAW's stock grew similarly to BIIB’s and similarly to CVM’s over the last 12 months.
BIIB's SMR Rating (71) in the Biotechnology industry is in the same range as CVM (99) and is in the same range as TRAW (100). This means that BIIB's stock grew similarly to CVM’s and similarly to TRAW’s over the last 12 months.
CVM's Price Growth Rating (34) in the Biotechnology industry is in the same range as BIIB (62) and is in the same range as TRAW (65). This means that CVM's stock grew similarly to BIIB’s and similarly to TRAW’s over the last 12 months.
CVM's P/E Growth Rating (49) in the Biotechnology industry is somewhat better than the same rating for BIIB (95) and is somewhat better than the same rating for TRAW (100). This means that CVM's stock grew somewhat faster than BIIB’s and somewhat faster than TRAW’s over the last 12 months.
| BIIB | CVM | TRAW | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 2 days ago 67% | 2 days ago 90% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 68% | 2 days ago 84% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 71% | N/A | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 71% | 2 days ago 83% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 56% | 2 days ago 83% | 2 days ago 78% |
| Advances ODDS (%) | 9 days ago 53% | 5 days ago 81% | 16 days ago 75% |
| Declines ODDS (%) | 3 days ago 70% | 26 days ago 90% | 8 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 62% | 2 days ago 90% | 2 days ago 83% |
| Aroon ODDS (%) | N/A | 2 days ago 78% | 2 days ago 83% |
Advertisement
TRAW and
Correlation & Price change
A.I.dvisor indicates that over the last year, TRAW has been loosely correlated with SLGL. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if TRAW jumps, then SLGL could also see price increases.
| Ticker / NAME | Correlation To TRAW | 1D Price Change % | ||
|---|---|---|---|---|
| TRAW | 100% | +2.67% | ||
| SLGL - TRAW | 47% Loosely correlated | +0.96% | ||
| RAPT - TRAW | 45% Loosely correlated | -5.39% | ||
| MDGL - TRAW | 39% Loosely correlated | +4.36% | ||
| CYTK - TRAW | 36% Loosely correlated | +4.06% | ||
| AVXL - TRAW | 35% Loosely correlated | +1.16% | ||
More | ||||